PDL BIOPHARMA INC's ticker is and the CUSIP is 69329YAG9. A total of 16 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,843,000 | -62.0% | 1,700,000 | -66.0% | 0.02% | -66.1% |
| Q3 2019 | $4,854,000 | -72.6% | 5,000,000 | -70.3% | 0.06% | -73.2% |
| Q2 2019 | $17,720,000 | -8.0% | 16,852,000 | 0.0% | 0.23% | -12.2% |
| Q1 2019 | $19,255,000 | +13.8% | 16,852,000 | 0.0% | 0.26% | +29.6% |
| Q4 2018 | $16,917,000 | +2.4% | 16,852,000 | 0.0% | 0.20% | +5.7% |
| Q3 2018 | $16,518,000 | +7.3% | 16,852,000 | 0.0% | 0.19% | -3.5% |
| Q2 2018 | $15,400,000 | -10.8% | 16,852,000 | 0.0% | 0.20% | -10.8% |
| Q1 2018 | $17,264,000 | +4.6% | 16,852,000 | 0.0% | 0.22% | +33.5% |
| Q4 2017 | $16,507,000 | -9.1% | 16,852,000 | +0.9% | 0.17% | -16.9% |
| Q3 2017 | $18,166,000 | +21.4% | 16,700,000 | 0.0% | 0.20% | +5.8% |
| Q2 2017 | $14,958,000 | +2.7% | 16,700,000 | 0.0% | 0.19% | -15.9% |
| Q1 2017 | $14,560,000 | +7.6% | 16,700,000 | 0.0% | 0.23% | +29.1% |
| Q4 2016 | $13,528,000 | – | 16,700,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SMH CAPITAL ADVISORS INC | 12,804,000 | $12,636,000 | 21.66% |
| Context Partners Fund, L.P. | 7,175,000 | $7,034,000 | 4.09% |
| Context Capital Management, LLC | 7,175,000 | $7,034,000 | 4.09% |
| Pinnacle Holdings, LLC | 3,260,000 | $3,217,213,000 | 1.11% |
| Venator Capital Management Ltd. | 2,000,000 | $1,960,000 | 0.98% |
| LINDEN ADVISORS LP | 26,617,000 | $26,292,000 | 0.80% |
| WHITEBOX ADVISORS LLC | 21,681,000 | $21,396,000 | 0.65% |
| WOLVERINE ASSET MANAGEMENT LLC | 16,852,000 | $16,518,000 | 0.19% |
| OAKTREE CAPITAL MANAGEMENT LP | 4,695,000 | $4,657,000 | 0.06% |
| AQR Arbitrage LLC | 3,150,000 | $3,124,000 | 0.04% |